---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-024480"
form_type: "8-K"
ticker: "TGTX"
cik: "0001001316"
company_name: "TG THERAPEUTICS, INC."
filed_at: "2025-08-04T23:59:59+00:00"
generated_at: "2026-05-17T21:18:17.202140+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# TG Therapeutics Q2 BRIUMVI revenue $138.8M (+91% YoY); raises FY guidance to $570-575M

## Summary
- Q2 2025 total revenue $141.1M; BRIUMVI U.S. net sales $138.8M, up 91% YoY vs $72.6M.
- Net income $28.2M in Q2 2025 vs $6.9M in Q2 2024; cash and securities $278.9M.
- Raises FY 2025 BRIUMVI U.S. net revenue guidance to $570-575M (prior $560M); total global revenue target ~$585M.
- R&D expense $31.8M (up from $17.6M) driven by subcutaneous development; SG&A $55.6M (up from $38.8M) for commercialization.
- Pipeline: Phase 3 ENHANCE trial for consolidated IV dosing ongoing; Phase 1 azer-cel in autoimmune diseases first patient dosed.

## SEC filing metadata
- accession: 0001437749-25-024480
- form_type: 8-K
- ticker: TGTX
- cik: 0001001316
- company_name: TG THERAPEUTICS, INC.
- filed_at: 2025-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001316/000143774925024480/0001437749-25-024480-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001316/000143774925024480/tgtx20250724_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-024480
- JSON: https://secwatch.observer/filing/0001437749-25-024480.json
- Plain text: https://secwatch.observer/filing/0001437749-25-024480.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.